Skip to main content

Tendon Injuries

1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK1278863Phase 1
Organogenesis
OrganogenesisCANTON, MA
1 program
NuShieldN/A2 trials
Active Trials
NCT07510412Recruiting200Est. Apr 2029
NCT03828916Unknown30Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
OrganogenesisNuShield
OrganogenesisNuShield

Clinical Trials (2)

Total enrollment: 230 patients across 2 trials

Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

Start: Mar 2026Est. completion: Apr 2029200 patients
N/ARecruiting

NuShield in Surgical Peroneal Tendon Repair

Start: Jan 2019Est. completion: Jun 202130 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 230 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.